Fibrinogen and other plasma proteins

Fibrinogen and other plasma proteins represent a collective group of soluble proteins found in the blood that are essential for maintaining vascular integrity and hemostasis. Fibrinogen, also known as Coagulation Factor I, is a large, complex glycoprotein that is converted by thrombin into insoluble fibrin, which polymerizes to form the primary structural component of blood clots [1.2.3, 1.3.1]. Other plasma proteins, including albumin, globulins, and various coagulation factors, contribute to the blood's osmotic pressure, transport capabilities, and the amplification of the clotting cascade [1.2.1, 1.4.2]. In clinical pharmacology, this group is often cited as the substrate for fibrinolytic and defibrinogenating agents; for instance, plasmin (activated by thrombolytic drugs like streptokinase or alteplase) degrades not only fibrin but also fibrinogen and other plasma proteins [1.3.2, 1.4.2]. This non-specific degradation can lead to a systemic lytic state, which is a significant therapeutic challenge. Therapeutic interventions targeting these proteins are primarily used to treat thrombotic disorders, such as ischemic stroke and myocardial infarction, by reducing blood viscosity or dissolving existing thrombi [1.1.1, 1.3.2]. However, these treatments carry a significant risk of major hemorrhage due to the depletion of essential clotting components [1.1.1, 1.4.2]. Additionally, plasma-derived fibrinogen concentrates are used as replacement therapy in patients with congenital or acquired fibrinogen deficiencies to restore hemostatic function [1.1.1].

Other names

Plasma proteinsCoagulation factorsFactor I and other plasma proteinsBlood proteins

Direct or indirect proteolytic degradation of fibrinogen and other plasma proteins to reduce blood viscosity or dissolve clots; replacement of deficient proteins to restore hemostasis.